Sponsor or institution

Clinical trials and research at Octapharma

• 8Clinical trials
• 39Countries

Newest trials

All recruiting trials (8)

• Panzyga to prevent major infections during autoimmune therapy

  This Phase 3 trial tests whether Panzyga can help prevent serious infections in adults with hypogammaglobulinemia who are receiving B-cell depletion therapy for autoimmune or rheumatic conditions.

  Recruiting at 11 sites Phase 3 Octapharma · Glendale, Arizona and 24 other locations · NCT07220915

• Treatment of acute hereditary angioedema with a plasma-derived C1 inhibitor

  This study is testing a new treatment using a plasma-derived C1 inhibitor to see if it can help people with hereditary angioedema manage their symptoms better than a placebo.

  Recruiting at 6 sites Phase 3 Octapharma · Centennial, Colorado and 26 other locations · NCT06361537

• Evaluating a new treatment for patients resistant to heparin during heart surgery

  This study is testing a new treatment called Atenativ to see if it can help heart surgery patients who don't respond to heparin feel better and have safer surgeries.

  Recruiting at 22 sites Phase 3 Octapharma · Stanford, California and 26 other locations · NCT06096116

• Using Nuwiq to manage bleeding in women and girls with Hemophilia A during surgery

  This study is testing if Nuwiq can help prevent bleeding during major surgeries for women and girls aged 12 and older with mild to moderate Hemophilia A.

  Recruiting at 13 sites Phase 4 Octapharma · San Antonio, Texas and 15 other locations · NCT05936580

• Using Nuwiq to manage bleeding in hemophilia A patients during major surgery

  This study is testing if Nuwiq can help prevent bleeding during major surgery for boys and men over 12 with severe hemophilia A who are already using another treatment called emicizumab.

  Recruiting at 17 sites Phase 4 Octapharma · Dallas, Texas and 17 other locations · NCT05935358

• Evaluating different doses of Panzyga for children with CIDP

  This study is testing different doses of Panzyga to see which one works best for children aged 2 to 17 with Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP).

  Recruiting at 6 sites Phase 3 Octapharma · Birmingham, Alabama and 5 other locations · NCT04929236

• Assessing Atenativ for patients with congenital antithrombin deficiency during surgery or delivery

  This study tests whether Atenativ can help prevent blood clots in patients with congenital antithrombin deficiency during surgery or childbirth.

  Recruiting at 30 sites Phase 3 Octapharma · Washington D.C., District of Columbia and 29 other locations · NCT04918173

• Evaluating the effectiveness and safety of FVIII concentrates in young haemophilia A patients

  This study is testing how well and safely a new treatment for hemophilia A works in young children who haven't had much treatment before.

  Recruiting at 33 sites Octapharma · Miami, Florida and 58 other locations · NCT03695978

Quick answers

How many clinical trials run by Octapharma are recruiting right now?

8, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.

Where are these trials running?

In 39 countries. The most sites are in United States (8 trials), France (5 trials), Serbia (5 trials), United Kingdom (5 trials), Germany (4 trials). Each study page lists its sites and which ones are recruiting.

What phases are they in?

Phase 3: 5, Phase 4: 2. Trials with no phase listed are usually device, behavioural or observational studies.

How do I join one?

Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.

Find the studies that fit you

A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.

Describe your situation →